Excellent work, Nice Design https://www.tca.nl/differin-gel-1.pdf implied incorrect differin 0.3 gel generic pine deep It looks like the end of the road for dual PPAR alpha/gamma agonists. Seven years ago, development of both Bristol-Myers Squibb and Merck & Co's Pargluva (muraglitazar) and AstraZeneca's Galida (tesaglitazar) was ended over safety concerns.